<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03364036</url>
  </required_header>
  <id_info>
    <org_study_id>MS700568_0022</org_study_id>
    <secondary_id>2017-002631-42</secondary_id>
    <nct_id>NCT03364036</nct_id>
  </id_info>
  <brief_title>Evaluation of the Onset of Action in Highly Active Multiple Sclerosis (MS)</brief_title>
  <official_title>A 2-year Prospective Study to Evaluate the Onset of Action of Mavenclad® in Subjects With Highly Active Relapsing Multiple Sclerosis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Merck KGaA</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Merck KGaA</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The main purpose of the study is to determine the onset of Mavenclad® action by frequent
      magnetic resonance imaging (MRI) assessment of the combined unique active (CUA) lesions in
      subjects with highly active relapsing multiple sclerosis (RMS).
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">April 30, 2018</start_date>
  <completion_date type="Anticipated">January 1, 2022</completion_date>
  <primary_completion_date type="Anticipated">July 1, 2020</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change From Baseline in Counts of Combined Unique Active (CUA) Magnetic Resonance Imaging (MRI) Lesions at Month 6</measure>
    <time_frame>Baseline, Month 6</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Counts of Immune Cell Subsets at Month 3, 6, 12, 15, 18 and 24</measure>
    <time_frame>Baseline, Month 3, 6, 12, 15, 18 and 24</time_frame>
    <description>Immune cell subsets will be analyzed by flow cytometry analysis.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">300</enrollment>
  <condition>Multiple Sclerosis</condition>
  <arm_group>
    <arm_group_label>Mavenclad®</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Mavenclad®</intervention_name>
    <description>Subjects will receive Mavenclad® 3.5 milligram per kilogram (mg/kg) of body weight over 2 years, administered as 1 treatment course of 1.75 mg/kg per year.</description>
    <arm_group_label>Mavenclad®</arm_group_label>
    <other_name>Cladribine</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Highly active RMS as defined by:

          -  One relapse in the previous year and at least 1 T1 Gadolinium (Gd)+ lesion or 9 or
             more T2 lesions, while on therapy with other disease modifying drugs (DMDs)

          -  Two or more relapses in the previous year, whether on DMD treatment or not.

          -  Expanded Disability Status Scale (EDSS) score less than equals to (&lt;=) 5.0.

          -  Other protocol defined inclusion criteria could apply.

        Exclusion Criteria:

          -  Previous exposure to drugs such as fingolimod, natalizumab, alemtuzumab, mitoxantrone
             and ocrelizumab.

          -  Positive hepatitis C or hepatitis B surface antigen test and/or hepatits B core
             antibody test for immunoglobulin G (IgG) and/or immunoglobulin M (IgM).

          -  Current or previous history of immune deficiency disorders including a positive human
             immunodeficiency virus (HIV) result.

          -  Currently receiving immunosuppressive or myelosuppressive therapy with, for example,
             monoclonal antibodies, methotrexate, cyclophosphamide, cyclosporine or azathioprine,
             or chronic use of corticosteroids.

          -  History of tuberculosis , presence of active tuberculosis, or latent tuberculosis

          -  Evidence or suspect of Progressive Multifocal Leukoencephalopathy (PML) in Magnetic
             Resonance Imaging (MRI).

          -  Active malignancy or history of malignancy.

          -  Other protocol defined exclusion criteria could apply.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Medical Responsible</last_name>
    <role>Study Director</role>
    <affiliation>Merck KGaA</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Merck KGaA Communication Center</last_name>
    <phone>+49 6151 72 5200</phone>
    <email>service@merckgroup.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Merck KGaA Communication Center</name>
      <address>
        <city>Darmstadt</city>
        <zip>64293</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>April 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 1, 2017</study_first_submitted>
  <study_first_submitted_qc>December 1, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">December 6, 2017</study_first_posted>
  <last_update_submitted>April 6, 2018</last_update_submitted>
  <last_update_submitted_qc>April 6, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">April 9, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Multiple sclerosis</keyword>
  <keyword>Mavenclad ®</keyword>
  <keyword>Cladribine</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sclerosis</mesh_term>
    <mesh_term>Multiple Sclerosis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cladribine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

